Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriol

Journal of Cutaneous Pathology

Volumn 23, Issue 5, 1996, Pages 419-430

  Lu, Irene ^a   Gilleaudeau, Pat ^a   McLane, John A ^b   Heftler, Noah ^a   Kamber, Markus ^b   Gottlieb, Scott ^a   Krueger, James G ^a   Gottlieb, Alice B ^c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; GAMMA INTERFERON; KERATIN; VITAMIN D DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EPIDERMIS CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATION; KERATINOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; PSORIASIS; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CALCITRIOL; CELL DIFFERENTIATION; CHEMOTAXIS, LEUKOCYTE; EPITHELIUM; HUMANS; INFLAMMATION; KERATINOCYTES; KERATINS; PSORIASIS; T-LYMPHOCYTES;

EID: 0029962470     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1996.tb01431.x     Document Type: Article

References (53)

1. Holick MF. Will 1,25-dihydroxyvitamin D3, MC 903, and their analogues herald a new pharmacologic era for the treatment of psoriasis? Arch Dermatol 1989: 125: 1692.
2. Gerritsen MJP, Rulo HFC, Vlijmen-Willems IV, Van Erp PEJ, Van de Kerkhof PCM. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. Br J Dermatol 1993: 128: 666.
3. Murdoch D, Clissold SP. Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992: 3: 415.
4. Kragballe K, Gjertsen BT, de Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991: 337: 193.
5. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocrine Reviews 1992: 13: 719.
6. Kim H-J, Abdelkader N, Katz M, McLane JA. 1,25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-betal on human keratinocytes in culture. J Cell Physiol 1992: 151: 579.
7. McLane JA, Katz M, Abdelkader N. Effect of 1,25-dihydrxyvitamin D3 on human keratinocytes grown under different culture conditions. In Vitro Cell Dev Biol 1990: 26: 379.
8. Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol 1987: 89: 253.
9. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte. pathogenic basis. Nature Medicine 1995: 1: 442.
10. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992: 98: 302.
11. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994: 180: 283.
12. Gottlieb AB, Krueger JG. The role of activated T lymphocytes in the pathogenesis of psoriasis. In: Dubertret L, ed. Psoriasis. Brescie, Italy: ISED press, 1994: 63.
13. Krueger JG, Gottlieb AB. Cellular signalling in psoriasis: growth factors, cytokines and eicosanoids. In: Dubertret L, ed. Psoriasis. Brescie, Italy: ISED press, 1994: 18.
14. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-RD molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986: 164: 1013.
15. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 1988: 167: 670.
16. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma-interferon-induced protein (IP-10) in psoriatic plaques. J Exp Med 1988: 168: 941.
17. Grossman RM, Krueger J, Yourish D, et al. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989: 86: 6367.
18. Gottlieb AB, Krueger JG. HLA region genes and immune activation in the pathogenesis of psoriasis. Arch Dermatol 1990: 126: 1083.
19. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990: 94: 135S.
20. Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992: 175: 1081.
21. Braunstein S, Kaplan G, Gottlieb AB, et al. GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. J Invest Dermatol 1994: 103: 601.
22. Baker BS, Griffiths CEM, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987: 116: 503.
23. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990: 126: 351.
24. Livden JK, Nilsen R, Bjerke JR, Matre R. In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 1989: 281: 392.
25. Sticherling M, Bornscheuer E, Schroder JM, Christophers E. Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol 1991: 96: 26.
26. Gillitzer R, Berger R, Mielke V, Muller C, Wollf K, Stingl G. Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol 1991: 97: 73.
27. Diezel W, Waschke SR, Sonnichsen N. Detection of interferon in the sera of patients with psoriasis, and its enhancement by PUVA treatment. Br J Dermatol 1983: 109: 549.
28. Bos JD, Krieg SR. Psoriasis infiltrating cell immunophenotype: changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. Acta Derma Venereol 1985: 65: 390.
29. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991: 127: 871.
30. Singer KH, Tuck DT, Sampson HA, Hall RP. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J Invest Dermatol 1989: 92: 746.
31. Springer TA. Adhesions receptors of the immune system. Nature 1990: 346: 425.
32. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984: 83: 88.
33. Hancock GE, Kaplan G, Cohn ZA. Keratinocyte growth regulation by the products of immune cells. J Exp Med 1988: 168: 1395.
34. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986: 315: 6.
35. Reichel H, Koeffler HP, Tobler A, Norman AW. lapha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987: 84: 3385.
36. Rigby WFC. The immunobiology of vitamin D. Immunol Today 1988: 9: 54.
37. Muller K, Rieneck K, Hansen MB, Bendtzen K. 1,25-dihydroxyvitamin D3-mediated suppression of T lymphocyte functions and failure of T cell-activating cytokines to restore proliferation. Immunol Lett 1992: 34: 37.
38. Lemire JM, Adams JS, Sakai R, Jordan SC. 1α,25-Dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984: 74: 657.
39. Lemire JM. Immunomodulatory role of 1,25-Dihydroxyvitamin-D3. J Cell Biochem 1992: 49: 26.
40. Manolagas SC, Provvedini DM, Murray FJ, Tsoukas CD, Deftos LJ. The antiproliferative effect of calcitriol on human periperal blood mononuclear cells. J Clin Endocrinol Metabol 1986: 63: 394.
41. Boyce ST, Ham RG. Cultivation, frozen storage, and clonal growth of normal human epidermal keratinocytes in serum-free media. J Tiss Cult Meth 1985: 9: 83.
42. Chen JC, Persons K, Uskokovic MR, Horst RL, Holick MF. An evaluation of 1,25-dihydroxyvitamin D3 analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism and the differentiation of human HL-60 cells. J Nutr Biochem 1993: 4: 49.
43. Gallati HI, Pracht J, Schmidt P, Haring P, Garotta G. A simple, rapid and large capacity ELISA for biologically active native and recombinant human IFN-gamma. J Biol Reg Homeostat 1987: 1: 109.
44. Eills CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study JAMA 1986: 256: 3110.
45. Gottlieb SL, Heftler NS, Gilleaudeau P, et al. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: A clinical and pathologic study. J Am Acad Dermatol 1995: 33: 637.
46. Glinski W, Obalek S, Langner A, Jablonska S, Haftek M. Defective function of T lymphocytes in psoriasis. J Invest Dermatol 1978: 70: 105.
47. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995: 182: 2057.
48. Granelli-Piperno A, Andrus L, Steinman RM. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells: kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 1986: 163: 922.
49. Ho VC, Griffiths CEM, Ellis CN, et al. Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic and pharmacokinetic study. J Am Acad Dermatol 1990: 22: 94.
50. Gupta AK, Brown MD, Ellis GN, et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989: 21: 1245.
51. Oxholm A, Oxholm P, Staberg B, Bendtzen K. Expression of interleukin-6-like molecules and tumor necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). Acta Derm Venerol (Stockh) 1989: 69: 385.
52. Tobler A, Miller CW, Norman AW, Koeffler HP. 1,25-Dihydroxyvitamin D3 modulates the expression of a lymphokine (granulocyte-mactrophage colony-stimulating factor) posttranscriptionally. J Clin Invest 1988: 81: 1819.
53. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994: 31 :68.